BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38135698)

  • 1. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient.
    Zhang S; Yan J; He L; Jiang Z; Jiang H
    Cancer Gene Ther; 2024 Mar; 31(3):484-494. PubMed ID: 38135698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN.
    Zhang J; Shen K; Xiao M; Huang J; Wang J; Wang Y; Hong Z
    Front Genet; 2023; 14():1198834. PubMed ID: 37396034
    [No Abstract]   [Full Text] [Related]  

  • 4. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
    Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
    Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
    Milosevic Feenstra JD; Nivarthi H; Gisslinger H; Leroy E; Rumi E; Chachoua I; Bagienski K; Kubesova B; Pietra D; Gisslinger B; Milanesi C; Jäger R; Chen D; Berg T; Schalling M; Schuster M; Bock C; Constantinescu SN; Cazzola M; Kralovics R
    Blood; 2016 Jan; 127(3):325-32. PubMed ID: 26423830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis.
    Xia J; Lu MZ; Jiang YQ; Yang GH; Zhuang Y; Sun HL; Shen YF
    Chin J Cancer Res; 2012 Mar; 24(1):72-6. PubMed ID: 23359764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
    Zulkeflee RH; Zulkafli Z; Johan MF; Husin A; Islam MA; Hassan R
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
    Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
    Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
    Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
    Nunes DP; Lima LT; Chauffaille Mde L; Mitne-Neto M; Santos MT; Cliquet MG; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2015 Oct; 55(3):236-40. PubMed ID: 26227853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wu Z; Zhang X; Xu X; Chen Y; Hu T; Kang Z; Li S; Wang H; Liu W; Ma X; Guan M
    J Hematol Oncol; 2014 Jul; 7():48. PubMed ID: 25023898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.
    Chaligné R; Tonetti C; Besancenot R; Roy L; Marty C; Mossuz P; Kiladjian JJ; Socié G; Bordessoule D; Le Bousse-Kerdilès MC; Vainchenker W; Giraudier S
    Leukemia; 2008 Aug; 22(8):1557-66. PubMed ID: 18528423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
    Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
    Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
    Maddali M; Kulkarni UP; Ravindra N; Arunachalam AK; Venkatraman A; Lionel S; Manipadam MT; Devasia AJ; Korula A; Fouzia NA; Abraham A; Srivastava A; George B; Balasubramanian P; Mathews V
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):13-20. PubMed ID: 33789164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation profile in Indian primary myelofibrosis patients and its clinical implications.
    Patil VR; Chandrakala S; Mantri S; Patil R; Wasekar N; Jijina F
    South Asian J Cancer; 2019; 8(3):186-188. PubMed ID: 31489296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.